The Outlook For Johnson & Johnson’s Immunology Drug Business

Johnson & Johnson’s immunology portfolio, which primarily consists of Remicade, Simponi and Stelara, accounts for around 15% of the company’s value, according to our estimates.December 05, 2017 at 01:55PM